Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: Study protocol for a randomized controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Humar, Atul ^a   Gill, John ^b   Johnston, Olwyn ^c   Fergusson, Dean ^d   House, Andrew A ^e   Lebel, Louise ^d   Cockfield, Sandra ^a   Kim, S Joseph ^f   Zaltzman, Jeff ^g   Cantarovich, Marcelo ^h   Karpinski, Martin ⁱ   Ramsay, Tim ^d   Knoll, Greg A ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

Author keywords

BK virus; Kidney transplantation; Levofloxacin; Polyomavirus; Quinolone; Randomized controlled trial

Indexed keywords

LEVOFLOXACIN;

ADULT; ARTICLE; BK VIRUS; BK VIRUS INFECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URINE; VIRUS REPLICATION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BK VIRUS; CANADA; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LEVOFLOXACIN; OFLOXACIN; PILOT PROJECTS; POLYOMAVIRUS INFECTIONS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS;

EID: 84879113418     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-185     Document Type: Article

References (44)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held P, Port F. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730. 10.1056/NEJM199912023412303, 10580071.
2. Russell JD, Beecroft M, Ludwin D, Churchill DN. The quality of life in renal transplantation-a prospective study. Transplantation 1992, 54:656-660. 10.1097/00007890-199210000-00018, 1412757.
3. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996, 50:235-242. 10.1038/ki.1996.307, 8807593.
4. Healthcare Systems Bureau, Division of Transplantation 2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006 2008, Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
5. BK virus. Am J Transplant 2004, 4(Suppl 10):89-91.
6. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007, 2(Suppl 1):36-46.
7. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005, 79:1277-1286. 10.1097/01.TP.0000156165.83160.09, 15912088.
8. Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, Mayr M. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010, 10:2615-2623. 10.1111/j.1600-6143.2010.03310.x, 21114642.
9. Cheeseman SH, Black PH, Rubin RH, Cantell K, Hirsch MS. Interferon and BK Papovavirus-clinical and laboratory studies. J Infect Dis 1980, 141:157-161. 10.1093/infdis/141.2.157, 6154110.
10. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006, 69:655-662. 10.1038/sj.ki.5000040, 16395271.
11. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006, 6:2000-2005. 10.1111/j.1600-6143.2006.01403.x, 16771813.
12. Almeras C, Foulongne V, Garrigue V, Szwarc I, Vetromile F, Segondy M. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008, 85:1099-1104. 10.1097/TP.0b013e31816a33d4, 18431228.
13. De Paolis P, Gervasio E, Tedesco M, Favaro A, Iappelli M, Abbate I, Capobianchi M, Di Giulio S. Impact of preemptive reduction of immunosuppression with serial monitoring for BK virus replication in renal transplant recipients undergoing short-term evaluation. Transplant Proc 2009, 41:1207-1209. 10.1016/j.transproceed.2009.03.091, 19460518.
14. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006, 10:920-922. 10.1111/j.1399-3046.2006.00575.x, 17096758.
15. Ryan J, Zanabli A, Cosio FG, Stegall MD, Larson TS, Griffin M. Outcomes of immunosuppression reduction in BK viremic kidney transplant recipients screened at 4 months post-transplant. Am J Transplant 2007, 7(Suppl 2):537.
16. Hardinger K, Koch M, Bohl D, Storch G, Brennan D. BK-Virus and the Impact of Pre-Emptive Immunosuppression Reduction: 5-Year Results. Am J Transplant 2010, 10:407-415. 10.1111/j.1600-6143.2009.02952.x, 3188431, 20055811.
17. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005, 5:218-227. 10.1111/j.1600-6143.2004.00692.x, 15643981.
18. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004, 4:135-141. 10.1111/j.1600-6135.2004.00736.x, 15504226.
19. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005, 41(Suppl 2):S144-S157.
20. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005, 40:528-537. 10.1086/427291, 15712075.
21. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007, 12:1-6.
22. Korzets A, Gafter U, Dicker D, Herman M, Ori Y. Levofloxacin and rhabdomyolysis in a renal transplant patient. Nephrol Dial Transplant 2006, 21:3304-3305. 10.1093/ndt/gfl396, 16968728.
23. Wagenlehner FM, Kinzig-Schippers M, Sorgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006, 28:551-559. 10.1016/j.ijantimicag.2006.07.026, 17101261.
24. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005, 5:582-594. 10.1111/j.1600-6143.2005.00742.x, 15707414.
25. Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005, 5:1926-1933. 10.1111/j.1600-6143.2005.00934.x, 15996241.
26. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992, 62:249-256. 10.1159/000187054, 1436333.
27. Repchinsky C. Compendium of Pharmaceuticals and Specialties 2007, Ottawa: Canadian Pharmacists Association.
28. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611-620. 10.1111/j.1600-6143.2004.00382.x, 15023154.
29. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl 4):S78-S86.
30. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl 4):S227-S233.
31. Hirsch HH, Drachenberg CB, Steiger J, Ramos E. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006, 577:160-173. 10.1007/0-387-32957-9_11, 16626034.
32. Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, Harland R, Thistlethwaite RJ, Garfinkel M, Atwood W, Jordan J, Sadhu M, Millis MJ, Williams J. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006, 81:704-710. 10.1097/01.tp.0000181149.76113.50, 16534472.
33. Kuypers DRJ, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, Naesens L, Vanrenterghem Y. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005, 5:1997-2004. 10.1111/j.1600-6143.2005.00980.x, 15996251.
34. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006, 81:117-120. 10.1097/01.tp.0000181096.14257.c2, 16421486.
35. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002, 347:488-496. 10.1056/NEJMoa020439, 12181403.
36. Humar A, Michaels M. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6:262-274. 10.1111/j.1600-6143.2005.01207.x, 16426310.
37. Pang XL, Doucette K, LeBlanc B, Cockfield SM, Preiksaitis JK. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J Clin Microbiol 2007, 45:3568-3573. 10.1128/JCM.00655-07, 2168526, 17855578.
38. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet 2006, 45:169-175. 10.2165/00003088-200645020-00003, 16485913.
39. Wrishko RE, Levine M, Primmett DR, Kim S, Partovi N, Lewis S. Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients. Transplantation 1997, 64:996-999. 10.1097/00007890-199710150-00011, 9381548.
40. Borrows R, Chusney G, Loucaidou M, James A, Van Tromp J, Cairns T. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolatemofetil-based renal transplantation. Ther Drug Monit 2007, 29:122-126. 10.1097/FTD.0b013e31803111d5, 17304160.
41. Moyses NM, Costa RS, Reis MA, Ferraz AS, Saber LT, Batista ME. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transplant 1997, 11:446-452.
42. Hibberd PL, Tolkoff-Rubin NE, Doran M, Delvecchio A, Cosimi AB, Delmonico FL, Auchincloss H, Rubin RH. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online J Curr Clin Trials 1992, Doc No 15.
43. Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003, 62:614-617. 10.1016/S0090-4295(03)00583-1, 14550427.
44. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003, 62:537-541. 10.1016/S0090-4295(03)00565-X, 12946763.